Aurora Cannabis shares saw an uptick following news that it has appointed U.S. billionaire Nelson Peltz as a strategic adviser and given him the option to buy a stake in the company.
The Edmonton-based cannabis company says it has granted Peltz options to purchase nearly 20 million common shares at $10.34 per share, slightly below Tuesday’s closing price.
The shares were up roughly 10 per cent in late morning trading, rising to $11.67 — up from Tuesday’s close of $10.64. The stock had been as high as $12.33 in earlier trading.
Peltz is CEO and founding partner of Trian Fund Management LP, a multi-billion dollar investment management firm. He also serves as the non-executive chairman of The Wendy’s Company and director of The Procter & Gamble Company, and was previously a director of H.J. Heinz Company and Mondelez International Inc.
“Nelson is a globally recognized business visionary with a strong track record of constructive engagement to generate accelerated, profitable growth and shareholder value across many industry verticals that are of great interest to us,” said Aurora’s chief executive Terry Booth in a statement.
Aurora said it will work with Peltz to explore potential partnerships for entry into certain market segments, and he will also advise on the cannabis producer’s global expansion strategy.
Peltz said Aurora has a “solid execution track record” and is poised to go to the “next level” across a range of industry verticals.
“I also believe that Canadian licensed producers, and Aurora in particular, are well positioned to lead in the development of the international cannabis industry as regulations evolve, with a strong, globally replicable operating model,” Peltz said in a statement.
Bringing in the high-profile adviser increases the likelihood of strategic partnerships for Aurora, said Martin Landry, an analyst with GMP Securities.
“Trian has been involved with a number of CPG (consumer packaged goods) companies such as PepsiCo, Dr Pepper Snapple, Procter & Gamble, Kraft Foods, Heinz, Mondelez, among others,” he said in a note to clients. “We believe he could be instrumental in facilitating discussions with large CPG companies.”
The arrangement with Peltz stands in contrast to the approach taken by Aurora’s Canadian peers, said Vivien Azer, an analyst with Cowen and Company.
While Tilray, Canopy Growth, and Cronos have partnered with established Fortune 500 companies — the latter two conceding significant equity stakes as well — Aurora has remained independent and brought in an adviser to guide its next phase of growth, she wrote in a note to clients.
“In light of Peltz’s past deals as an activist, we do not view the announcement as a step towards driving change to the existing business model (e.g., not a break up story),” Cowen said. “Rather, Peltz brings a network of relationships with large potential strategic companies that ACB could partner with across medical and consumer applications. In addition, we think ACB will be more patient in partnership selection than its peers, particularly regarding equity investment.”
The options granted to Peltz will become effective gradually over a four-year period on a quarterly basis, with accelerated vesting if specified events occur. Those events include the consummation of certain transactions and the closing price of Aurora’s common shares being at least $31.02 and additionally $41.36 for a specified number of trading days.
- CBC News services keep Canadians at home and abroad informed about their communities, their country and the world. CBC/Radio-Canada is the country's largest news organization, employing more than 800 journalists in Canada and around the globe. Their stories appear on CBC Television, CBC Radio, CBCNews.ca and CBC News Network.
- News2019.03.22B.C. naturopath linked to illegal pot trade has licence cancelled
- News2019.03.21Saskatchewan Budget 2019: Government touts balanced budget, says no new taxes
- News2019.03.21Pot sector players welcome edibles tax change, disappointed medical tax remains
- News2019.03.20Smoking strong pot daily raises psychosis risk, study finds